Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine

NCT01578070 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: 0.2μg Act-HIB®
BIOLOGICAL: ViscoGel® and 0.2μg Act-HIB®
BIOLOGICAL: ViscoGel® and 2μg Act-HIB®
BIOLOGICAL: 2μg Act-HIB®
BIOLOGICAL: 10μg Act-HIB®

Sponsor

Viscogel AB

Collaborators

[object Object]
[object Object]